Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide

J Clin Pharmacol. 2008 Nov;48(11):1339-49. doi: 10.1177/0091270008321941. Epub 2008 Aug 29.

Abstract

Effects of single and multiple doses of oral ketoconazole on roflumilast and its active metabolite, roflumilast N-oxide, were investigated in healthy subjects. In study 1, subjects (n = 26) received oral roflumilast 500 microg once daily for 11 days and a concomitant 200-mg single dose of ketoconazole on day 11. In study 2, subjects (n = 16) received oral roflumilast 500 microg on days 1 and 11 and a repeated dose of ketoconazole 200 mg twice daily from days 8 to 20. Coadministration of single-dose ketoconazole with steady-state roflumilast increased the AUC of roflumilast by 34%; C(max) was unchanged. For roflumilast N-oxide, AUC and C(max) decreased by 12% and 20%, respectively. Repeated doses of ketoconazole increased the AUC and C(max) of roflumilast by 99% and 23%, respectively; for roflumilast N-oxide, AUC was unchanged, and C(max) decreased by 38%. No clinically relevant adverse events were observed. Coadministration of ketoconazole and roflumilast does not require dose adjustment of roflumilast.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aminopyridines / adverse effects
  • Aminopyridines / blood*
  • Aminopyridines / pharmacokinetics*
  • Antifungal Agents / administration & dosage
  • Antifungal Agents / adverse effects
  • Antifungal Agents / pharmacology*
  • Benzamides / adverse effects
  • Benzamides / blood*
  • Benzamides / pharmacokinetics*
  • Cyclopropanes / adverse effects
  • Cyclopropanes / blood
  • Cyclopropanes / pharmacokinetics
  • Cytochrome P-450 CYP3A
  • Cytochrome P-450 CYP3A Inhibitors
  • Female
  • Humans
  • Ketoconazole / administration & dosage
  • Ketoconazole / adverse effects
  • Ketoconazole / pharmacology*
  • Male
  • Phosphodiesterase 4 Inhibitors*
  • Young Adult

Substances

  • Aminopyridines
  • Antifungal Agents
  • Benzamides
  • Cyclopropanes
  • Cytochrome P-450 CYP3A Inhibitors
  • Phosphodiesterase 4 Inhibitors
  • Roflumilast
  • Cytochrome P-450 CYP3A
  • CYP3A4 protein, human
  • roflumilast N-oxide
  • Ketoconazole